Literature DB >> 3280490

Angiotensin converting enzyme inhibitors. Properties and side effects.

H Gavras1, I Gavras.   

Abstract

The purpose of this brief review is to separate the characteristic properties and side effects attributable to the pharmacology of the whole class of angiotensin converting enzyme (ACE) inhibitors from those attributable to the chemical structure and kinetics of each particular ACE inhibitor. The former would be predictable and probably similar for all agents and, therefore, would be expected to recur with each agent, whereas the latter are likely to be characteristic of individual compounds and may be avoidable by changing to another compound with similar pharmacology but different molecular structure.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3280490     DOI: 10.1161/01.hyp.11.3_pt_2.ii37

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  16 in total

1.  Pharmacological activity and safety of trandolapril (RU 44570) in healthy volunteers.

Authors:  F De Ponti; C Marelli; L D'Angelo; M Caravaggi; L Bianco; S Lecchini; G M Frigo; A Crema
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Hemodynamic effects of benazepril, an angiotensin-converting enzyme inhibitor, as studied in conscious normotensive dogs.

Authors:  T Ishibashi; S Tatebe; A Mitomi; M Tanaka; S Imai
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

3.  Metalloprotein-inhibitor binding: human carbonic anhydrase II as a model for probing metal-ligand interactions in a metalloprotein active site.

Authors:  David P Martin; Zachary S Hann; Seth M Cohen
Journal:  Inorg Chem       Date:  2013-05-24       Impact factor: 5.165

Review 4.  Angiotensin converting enzyme inhibitors and moderate hypertension.

Authors:  D McAreavey; J I Robertson
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

5.  Reference-based pricing of prescription drugs: exploring the equivalence of angiotensin-converting-enzyme inhibitors.

Authors:  C Bourgault; E Elstein; J Le Lorier; S Suissa
Journal:  CMAJ       Date:  1999-08-10       Impact factor: 8.262

6.  Angiotensin Type 1 Receptor Blockers in Heart Failure.

Authors:  Khuraijam Dhanachandra Singh; Sadashiva S Karnik
Journal:  Curr Drug Targets       Date:  2020       Impact factor: 3.465

7.  Effect on insulin sensitivity of angiotensin converting enzyme inhibitors with or without a sulphydryl group: bradykinin may improve insulin resistance in dogs and humans.

Authors:  M Uehara; H Kishikawa; S Isami; K Kisanuki; Y Ohkubo; N Miyamura; T Miyata; T Yano; M Shichiri
Journal:  Diabetologia       Date:  1994-03       Impact factor: 10.122

Review 8.  Renin inhibition.

Authors:  H D Kleinert
Journal:  Cardiovasc Drugs Ther       Date:  1995-10       Impact factor: 3.727

Review 9.  Pharmacological management of hypertension in paediatric patients. A comprehensive review of the efficacy, safety and dosage guidelines of the available agents.

Authors:  K Miller
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

10.  Angiotensin-(1-7) contributes to insulin-sensitizing effects of angiotensin-converting enzyme inhibition in obese mice.

Authors:  Justin Loloi; Amanda J Miller; Sarah S Bingaman; Yuval Silberman; Amy C Arnold
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-10-09       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.